Fig. 6: Knockdown of PGAM2 enhances sorafenib sensitivity of HCC cells. | npj Precision Oncology

Fig. 6: Knockdown of PGAM2 enhances sorafenib sensitivity of HCC cells.

From: Hepatocellular carcinoma cells downregulate PGAM2 via SIRT2-mediated deacetylation modification to enhance aerobic glycolysis

Fig. 6

A–C Cell viability of controls and PGAM2 knockdown HCC cell lines treated with sorafenib for 48 h was detected by cck8 assay. D–F Cell viability of controls and PGAM2 knockdown HCC cell lines treated with or without sorafenib (40 μM for HepG2 and SNU449, 10 μM for SNU387) for 48 h was detected by cck8 assay. G Diagram illustrates treatment groups and timetable of injection of sorafenib or AGK2. H Tumor volume was measured with indicated treatment (n = 4). I Imaging of tumors in vivo and derived from mice (n = 4). J Expression level of SIRT2 in normal and sorafenib resistant Huh7 cell lines based on TCGA database. K Detection of SIRT2 in normal and sorafenib resistant HepG2 cell lines by western blot. L, M Kaplan–Meier curve of overall survival and progression free survival of HCC patients after sorafenib treatment according to SIRT2 expression in tumors based on TCGA database. N Cell viability detection of normal and sorafenib resistant HepG2 cell lines treated with sorafenib for 48 h by cck8. O Cell viability detection of sorafenib resistant HepG2 cell line treated with sorafenib and AGK2 alone or in combination for 48 h. SR sorafenib resistant, *p < 0.05, **p < 0.01, ***p < 0.001, ns no significance.

Back to article page